KRAS and pachyonychia congenita: KRAS mutations have been detected in about 90% of pre-neoplastic non-invasive lesions (low-grade pancreatic intraepithelial neoplasia) (51), though more rarely at more advanced stages of PC, suggesting a ‘common ground’ for early PC development.